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Transcription activator-like effector nucleases
(TALENs) are a new class of engineered nucleases
that are easier to design to cleave at desired sites
in a genome than previous types of nucleases. We
report here the use of TALENs to rapidly and effi-
ciently generate mutant alleles of 15 genes in
cultured somatic cells or human pluripotent stem
cells, the latter for which we differentiated both the
targeted lines and isogenic control lines into various
metabolic cell types. We demonstrate cell-autono-
mous phenotypes directly linked to disease—dyslipi-
demia, insulin resistance, hypoglycemia, lipodystro-
phy, motor-neuron death, and hepatitis C infection.
We found little evidence of TALEN off-target effects,
but each clonal line nevertheless harbors a significant
number of unique mutations. Given the speed and
ease with which we were able to derive and charac-
terize these cell lines, we anticipate TALEN-mediated
genome editing of human cells becoming a mainstay
for the investigation of human biology and disease.
INTRODUCTION
The study of human disease has been facilitated by the ability to
identify the gene mutations responsible; at the same time, it has
been hampered by the lack of an inexhaustible supply of easily
accessible tissues from patients bearing those mutations.
Another limitation is that many gene mutations that would be238 Cell Stem Cell 12, 238–251, February 7, 2013 ª2013 Elsevier Incinformative for disease biology if they could be studied in isolated
cells are incompatible with human life (i.e., embryonic lethal).
Classical gene-targeting technology via homologous recombina-
tion has proven to be an invaluable tool of experimental biology
through its use in mouse embryonic stem cells for generating
germline knockout and knockin mice; however, its use in mam-
malian systems has been limited primarily to studies in mice. In
many cases, mice do not faithfully phenocopy human physiology
and disease, e.g., cholesterol metabolism, coronary artery
disease, and human hepatitis C virus (HCV) infection. The emer-
gence of genome editing with engineered nucleases, as well as
human pluripotent stem cell (hPSC) technology and differentia-
tion protocols to obtain a variety of cell and tissue types in vitro,
now make it possible to rapidly interrogate the effects of genetic
modification in otherwise isogenic human model systems.
Transcription activator-like effector nucleases (TALENs) are
a new class of engineered nucleases that, due to their modular
domain structure, have proven more straightforward to design
and construct for performing genome editing than other types
of nucleases (Bogdanove and Voytas, 2011). TALENs are typi-
cally designed as a pair that binds to genomic sequences flank-
ing a target site and generates a double-strand break, which
is repaired by the cell using either homology-directed repair
(HDR) or the error-prone process of nonhomologous end-joining
(NHEJ) (Christian et al., 2010; Li et al., 2011; Miller et al., 2011;
Hockemeyer et al., 2011). NHEJ can be exploited to introduce
small insertions or deletions (indels) resulting in frameshift muta-
tions that effectively knock out a protein-coding gene. An exog-
enously introduced double-stranded DNA or single-stranded
DNA oligonucleotide (ssODN) can serve as a repair template
for HDR to incorporate an alteration into the genome (Soldner
et al., 2011). In principle, TALEN pairs can be generated de
novo with standard molecular biology techniques in a matter of.
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the utility, efficiency, and rapidity of TALEN technology in gener-
ating human cellular models with which to derive new biological
insights, we created mutations in 15 genes and performed
detailed phenotypic analysis of four genes for which novel
roles in disease biology have emerged in recent years—APOB,
SORT1, AKT2, and PLIN1.
RESULTS
Modular Assembly and Use of TALENs for Efficient and
Rapid Genome Editing
TheDNA-bindingdomain of a TALENcomprisesan array of 33- to
35-amino-acidmonomers that are ‘‘coded’’ to recognize andbind
specificDNAbasepairs (bp) in a 1:1 fashion (Moscou andBogda-
nove, 2009;Bochet al., 2009).Webuilt uponpreviouslydescribed
modular Golden Gate methodologies to allow assembly of mul-
tiple DNA fragments in an ordered fashion (Li et al., 2011; Cermak
et al., 2011), such that a single ligation of preassembled tetramers
and trimers generates TALENs that recognize any 15 bp recogni-
tion site in the genome (Figure 1; Figure S1 available online). This
assemblymethod requiresonly1–2days for completionand isnot
prone to errors that complicate methods that rely on PCR ampli-
fication of monomers. Furthermore, we have developed a set of
optimized vectors and methods for the delivery of TALENs into
mammalian cells and, in particular, hPSCs. In brief, we transfect
or electroporate TALEN pairs into cells and then subject them to
fluorescence-activated cell sorting (FACS) 48 hr posttransfection
based on fluorescent-marker expression. We replate the sorted
cells at low density and allow them to recover and grow for
1 week, resulting in the formation of distinct single colonies.
Colonies are expanded, genomic DNA purified, and mutations
analyzed by PCR, agarose-gel screening, and Sanger sequenc-
ing (Figure 1 and Figure S1). The entire process fromstart to finish
can be completed in less than one month.
Utilizing these methods, we generated TALEN pairs to target
16 distinct sites in 15 genes in human somatic cell lines, human
embryonic stem cell (hESC) lines, or human induced pluripotent
stem cell (iPSC) lines; the alterations included a variety of
knockout mutations as well as a knockin missense mutation
and a functional frameshift mutation (Table 1). We observed
that the efficiency of mutation varied by genomic location as
well as among different cell lines, with indels from NHEJ occur-
ring in roughly 2% to 34% of clones screened and the efficiency
of knockin by HDR occurring at a frequency of 1.6%. We then
proceeded to perform detailed phenotypic analyses of cells
harboring mutations in four human disease-related genes—
APOB, SORT1, AKT2, and PLIN1.
APOB Is Required for HCV Replication
APOB, which encodes apolipoprotein B, the core protein of very-
low-density lipoprotein and low-density lipoprotein (LDL) parti-
cles that transport cholesterol and triglycerides from the liver
to other tissues via the bloodstream, has been suggested as
playing a critical role in HCV infection. In HCV models using
cultured human HuH-7 hepatoma cells, RNA interference result-
ing in partial knockdown of APOB expression has been reported
to reduceHCV secretion, albeit not HCV replication (Huang et al.,
2007; Nahmias et al., 2008); however, another report has sug-Cegested that apolipoprotein E, but not apolipoprotein B, is neces-
sary for HCV production (Jiang and Luo, 2009). Thus, the impor-
tance of APOB and precise points of interaction with the HCV
lifecycle remain to be determined. We sought to address this
question by generating APOB knockout HuH-7 cells.
The human APOB gene encodes a 512 kDa protein termed
apoB-100. We designed a TALEN pair targeting a site in exon
13 (Figure 2A); frameshift mutations at the site would generate
truncated proteins about 12.5% of the size of apoB-100
(apoB-12.5). We transfected a clonal line of HuH-7 with high ex-
pression of CD81 (a coreceptor for HCV entry, HuH-7 [CD81hi])
with the APOB TALEN pair. Following FACS with a cotranslated
fluorescent marker, replating of sorted cells at a limiting dilution,
and expansion of single clones, we found that of 126 screened
clones, indels were present in nine clones (Figure S2A), of which
four had exon 13 frameshift mutations in both alleles (Figure 2A).
Compared to wild-type controls from the same set of screened
clones, APOB knockout cells had no detectable intracellular
apoB protein, no secreted apoB mass in the media, and <3%
APOB messenger RNA (mRNA) expression, consistent with
nonsense-mediated mRNA decay (Figures 2B, 2C, and 2D).
We infected APOB–/– and wild-type cells with the tissue-
culture-infectious HCV strain JFH-1. The APOB–/– cells had
significantly lower intracellular HCV RNA levels (74% reduction,
p = 0.006), with minimal detectable HCV core protein (Figures 2B
and 2E). Reintroduction of apoB-100 protein into the APOB–/–
cells by adding LDL particles to the media, allowing for cellular
LDL uptake, resulted in partial restoration of HCV core protein
levels, arguing that the HCV replication defect was the result of
loss of APOB function rather than an off-target effect of the
TALENs (i.e., mutagenesis at other sites in the genome) (Fig-
ure 2B). Together, these data suggest that apoB-100 is integral
to the HCV viral life cycle and that APOB-targeting therapeutics
(e.g., mipomersen) may have efficacy in treating HCV-infected
patients.
Isogenic Disease Models in hPSCs
We found that the karyotype of the HuH-7 cells was severely
abnormal (Figure S2B)—fortuitously, it harbored two APOB
alleles, in contrast to SORT1, with at least five alleles—high-
lighting the disadvantages of cultured tumor cell lines for
rigorous genetic studies. hPSCs offer several advantages: they
can maintain stable genomes with normal karyotypes while
propagated in culture (Figure S2B), preserving correct gene
dosage; they can be differentiated into a variety of cell types, ex-
tending studies beyond a single cell type; and they can yield
human cell types that are not available as cultured cell lines,
e.g., adipocytes and motor neurons.
These advantages are mitigated by the significant variability in
differentiation capacity and phenotypic characteristics among
different hPSC lines, particularly among iPSC lines. This vari-
ability is attributed to differences in genetic background, in
epigenetic state, and in derivation of the cell lines and adaptation
to culture, among other factors. In this variability lies the potential
for confounding of any phenotypic differences observed among
differentiated cell lines generated to serve as disease models or
controls—a significant weakness of studies in which a few iPSC
lines from patients are compared with a few iPSC lines from
healthy individuals, as has been the case with most publishedll Stem Cell 12, 238–251, February 7, 2013 ª2013 Elsevier Inc. 239
Figure 1. Schematic of System for Efficient and Rapid Genome Editing with TALENs
GFP, green fluorescent protein; RFP, red fluorescent protein; NLS, nuclear localization signal; N-term; N-terminal doman; C-term, C-terminal domain. See also
Figure S1.
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be reliably attributed to the effects of disease mutations. We
demonstrated this cell line-to-cell line variability by differenti-
ating two hESC lines, HUES 1 and HUES 9, into hepatocyte-
like cells (HLCs) using an adapted protocol (Si-Tayeb et al.,
2010) (Figure S3). We found that there were significant differ-
ences in the amounts of apoB and albumin secreted by the240 Cell Stem Cell 12, 238–251, February 7, 2013 ª2013 Elsevier Inctwo cell lines and retained in the media (Figure S4A); when
apoB mass was normalized to albumin mass, there was a
2-fold difference between the two lines (p = 0.0001).
Using genome editing to generate isogenic cell lines that differ
only with respect to a singlemutation of interest provides a supe-
rior study design, because the cell lines have the same origin and
would thus be matched in genetic background, epigenetic state,.
Table 1. Targeting Efficiency of TALENs at 16 Loci in 15 Genes in Various Cell Types








AKT2 TCCCTTCCTGCCTCATTTCAGGTGAATACATCAAGACCTGGAGGCCA HUES 9 192 17 8.9%
AKT2 E17K TCCCTTCCTGCCTCATTTCAGGTGAATACATCAAGACCTGGAGGCCA HUES 9 192 3b 1.6%
ANGPTL3 TCAAAACTTGAAAGCCTCCTAGAAGAAAAAATTCTACTTCAACAAAA HUES 9 424 84 19.8%
APOB TAAGCGACTGGCTGCCTATCTTATGTTGATGAGGAGTCCTTCACA HuH-7 126 9 7.1%
ATGL TTGCTGGCGTTGCCCCCCGCCCGCCCCCACGGCCCAGAGGACAAGGA HUES 9 192 28 14.6%
C6orf106 TGGAGGGCATGGACGTAGACCTGGACCCGGAGCTGATGCAGAAGTTCA HUES 9 216 13 6.0%
CIITA TAACAGCGATGCTGACCCCCTGTGCCTCTACCACTTCTATGACCAGA BJRiPS 292 37 12.7%
CELSR2 TGCTGGCTCGGCTGCCCTGAGGTTGCTCAATCAAGCACAGGTTTCAA HUES 1 506 18 3.5%
CFTR TGGAATCACACTGAGTGGAGGTCAACGAGCAAGAATTTCTTTAGCA CF-RiPS 140 3 2.1%
GLUT4 TGGTCCTTGCTGTGTTCTCTGCGGTGCTTGGCTCCCTGCAGTTTGGGTA HUES9 155 52 33.5%
LINC00116 TCAGAGAGGACACTGCAGTTGTCCGTGCTAGTAGCCTTCGCTTCTGGA HUES 9 88 26 29.5%
NLRC5 TGGAGCTGTCTTGTGAGGCTGCTCACCAAAGACCCAGAATGGCTGAA BJ-RiPS 83 6 7.2%
PLIN1 TGACAACGTGGTGGACACAGTGGTGCATTACGTGCCGGTGAGTACCA HUES 9 293 70 23.8%
PLIN1 TGACAACGTGGTGGACACAGTGGTGCATTACGTGCCGGTGAGTACCA BJ-RiPS 439 29 6.6%
SORT1
(exon 2)
TGATGATCTCAGAGGCTCAGTATCCTTGTCCTGGGTTGGAGATAGCA HUES 1 576 128 22.2%
SORT1
(exon 3)
TGGTAATTATGACTTTTGGACAGTCCAAGCTATATCGAAGGTGAGATCA HUES 9 192 21 10.9%
TRIB1 TCTTCAAGCAGATTGTCTCCGCCGTCGCCCACTGCCACCAGTCAGCCA HUES 9 169 41 24.2%
TTN TTGAGGCTCCTTAATGATGACAGAAGAGAAGGCTTCTCTGGGTTCA BJ-RiPS 250 17 6.8%
TALENs, transcription activator-like effector nucleases.
aHUES 1 and HUES 9 are human embryonic stem cell lines (Cowan et al., 2004); BJ-RiPS and CF-RiPS are induced pluripotent stem cell lines (Warren
et al., 2010); and HuH-7 cells are cultured human hepatocellular carcinoma cells.
bSuccessfully inserted E17K knockin mutation using single-stranded DNA oligonucleotide.
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This wouldminimize confounding of the experiment and allow for
more confidence in concluding that any phenotypic differences
are secondary to the mutation. For these reasons, our subse-
quent studies were all performed in genome-edited hESCs.
SORT1 Mediates Diverse Cellular Functions in
Hepatocytes, Adipocytes, and Neurons
SORT1 (encoding sortilin) was recently discovered through
genome-wide association studies to regulate human blood
LDL cholesterol levels and risk for coronary artery disease, via
the modulation of the hepatic secretion of apoB-100-containing
particles into the bloodstream; however, conflicting studies in
humans and mice disagree about the direction of the effect of
sortilin on apoB secretion (Musunuru et al., 2010; Kjolby et al.,
2010). Human genetic studies have found that SNPs associated
with increased hepatic SORT1 expression are also associated
with decreased blood LDL cholesterol levels (Musunuru et al.,
2010). Knockdown and overexpression of Sort1 in mouse liver
suggested that sortilin functions to decrease hepatocyte apoB
secretion (Musunuru et al., 2010). In contrast, a study of Sort1
knockout mice suggested that sortilin increases hepatocyte
apoB secretion (Kjolby et al., 2010).
We targeted exon 2 in the hESC line HUES 1 and, in a single
round of TALEN targeting, generated three clones that were
compound heterozygous for frameshift mutations (out of 576
clones screened) and confirmed that they lacked sortilin proteinCe(Figures 3A and 3B). In parallel, we targeted exon 3 in the hESC
line HUES 9 and obtained two knockout clones (out of 192
clones screened). We differentiated two SORT1–/– and two
wild-type HUES 1 clones or two SORT1–/– and two wild-type
HUES 9 clones into HLCs using an adapted protocol (Si-Tayeb
et al., 2010) (Figure S3). Measuring the levels of apoB as well
as albumin and apoA-I (reference controls) secreted from the
HLCs and retained in the media, we found that knockout cells
had significantly increased apoB mass (HUES 1: 117% increase
in apoB/albumin ratio, p = 0.04; HUES 9: 65% increase in apoB/
albumin ratio, p = 0.05) (Figure 3C and Figure S4B). We infected
knockout HUES 1 HLCs or HUES 9 HLCs with a lentivirus ex-
pressing the SORT1 complementary DNA (cDNA) or a control
lentivirus and found that reconstitution of SORT1 to the levels
observed in wild-type HUES 1 or HUES 9 HLCs resulted in
normalization of the apoBmass (Figure 3D and Figure S4C), con-
firming that the observed differences in apoB mass are specific
to SORT1 function and not the result of off-target effects. We
found that secreted levels of additional hepatic proteins—
ANGPTL4, ANGPTL6, HGF, and FGF-19—did not differ among
the various experimental conditions (Figure S4D), nor did
mRNA levels of APOB and other lipid-related genes such as
HMGCR, LDLR, and SREBP1 (Figure S4E). Our data suggest
that, in humans, sortilin acts in hepatocytes to reduce apoB-con-
taining particle levels in the blood, resulting in lower cholesterol
levels and reduced risk of coronary artery disease—consistent
with human genetic studies (Musunuru et al., 2010) and, notably,ll Stem Cell 12, 238–251, February 7, 2013 ª2013 Elsevier Inc. 241
Figure 2. APOB Is Important for HCV
Replication
(A) Generation of APOB knockout HuH-7 clones
with TALENs targeting exon 13. Boxes indicate the
TALEN binding sites. Deletions, insertions, and
duplications in the two alleles of each clone are
indicated. The 26 bp insertion and 8 bp duplication
(asterisk) in clone A are 50-GAGTCGCTTCT
CCGGGAGATAAGTCA-30 and 50-GACTGGCT-30,
respectively.
(B) Left panel, western blot using whole-cell
lysates from two wild-type (WT) and four knockout
(KO) HuH-7 cell lines (clones A–D). Right panel,
western blot from a wild-type clone and a
knockout clone (clone A) infected with or without
JFH-1 virus and incubated with or without LDL
particles. The same wild-type clone and knockout
clone (clone A) were used for all subsequent
experiments.
(C) Left panel, apoB ELISAs performed on condi-
tioned media from cells; values are normalized to
the level in the wild-type clone. Right panel, APOB
mRNA expression by qRT-PCR from whole-cell
lysates; expression is indicated as the fold change
of 2–DDCt with reference to 18S ribosomal RNA
(rRNA), normalized to the level in the wild-type
clone.
(D) Immunocytochemistry for apoB.
(E) HCV RNA levels by qRT-PCR from clones in-
fected with JFH-1 virus; expression is indicated
as the fold change of 2–DDCt with reference to
GAPDH, normalized to the level in the wild-type
clone.
The error bars show SEM from experiments with
biological replicates, N = 3. p values were calcu-
lated with an unpaired t test. See also Figure S2.
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(Kjolby et al., 2010).
SORT1 has also been suggested as playing an important role
in regulating blood glucose levels by modulating insulin-depen-
dent translocation of the fat- and muscle-specific glucose
transporter, Glut4, to the plasma membrane via the formation
and transport of Glut4 storage vesicles, based on studies in
cultured mouse 3T3-L1 cells (Shi and Kandror, 2005). We differ-
entiated two SORT1–/– and two wild-type HUES 1 clones into
white adipocytes using a recently published protocol (Ahfeldt
et al., 2012), and we observed a substantial increase in glu-
cose uptake in wild-type adipocytes upon treatment with insulin
(63% increase, p = 0.009), but not in SORT1–/– adipocytes (Fig-
ure S5A). We infected the knockout adipocytes with a SORT1
or control lentivirus and found that reconstitution of SORT1
restored insulin-responsive glucose uptake (60% increase,242 Cell Stem Cell 12, 238–251, February 7, 2013 ª2013 Elsevier Inc.p = 0.002), confirming that the loss of
insulin response in the knockout adipo-
cytes was specific to SORT1 function
and not the result of off-target effects
(Figure 3E and Figure S5B). Thus,
SORT1 appears to be critical for insulin-
responsive glucose uptake in human
adipocytes and may play a role in insulin
sensitivity in humans.Finally, SORT1 has also been implicated in the viability and
function of neurons (Nykjaer and Willnow, 2012). In motor
neurons, sortilin has been found to regulate neuronal survival
during a temporally and spatially specific period of programmed
cell death. Specifically, induction of motor-neuron cell death
by the proform of brain-derived neurotrophic factor (proBDNF)
has been reported to be dependent on the presence of
sortilin (Teng et al., 2005; Taylor et al., 2012). We differentiated
two SORT1–/– and two wild-type HUES 9 clones into TUJ1+
ISL-1+ motor neurons using an adapted protocol (Di Giorgio
et al., 2008; Chambers et al., 2009) and observed that
although both SORT1–/– and wild-type hPSCs generated similar
numbers of motor neurons (Figure S5C), wild-type motor
neurons exhibited a substantial reduction after 3 days of
proBDNF treatment (23% reduction, p = 0.004), whereas
SORT1–/– motor neurons were unaffected (Figures 3F and 3G).
Figure 3. SORT1 Reduces Hepatocyte-Secreted ApoB Mass, Is Important for Insulin-Responsive Glucose Transport in Adipocytes, and
Mediates proBDNF-Induced Motor-Neuron Death
(A) Generation of SORT1 knockout hPSC clones with TALENs targeting exon 2 or exon 3. Boxes indicate the TALEN binding sites. Deletions and insertions in the
two alleles of each clone are indicated. The 17 bp insertion (asterisk) in clone B is 50-TGCTATCTCCAACCAGG-30.
(B) Western blot for sortilin and qRT-PCR for SORT1 mRNA in wild-type and knockout HUES 1 clones (clones A–C); mRNA expression is indicated as the fold
change of 2–DDCt with reference to 18S rRNA, normalized to the mean level in the wild-type clones.
(C) Albumin and apoBmassmeasured by ELISA inmedia collected fromwild-type and knockout HLCs (two clones each; A andB for HUES 1, D and E for HUES 9),
normalized to mean levels in wild-type HLCs. N = 3 for HUES 1, N = 6 for HUES 9.
(D)Western blots of lysates and ELISAs inmedia fromwild-type and knockout HLCs (one clone each, A for HUES 1; two clones each, D and E for HUES 9) infected
with SORT1- or GFP-expressing lentivirus, normalized to mean levels in wild-type HLCs. N = 2 for HUES 1, N = 6 for HUES 9.
(E) Ratios of glucose uptake to total protein content in wild-type and knockout HUES 1 adipocytes (one clone each; clone A) infected with SORT1-expressing or
control lentivirus and treated with or without insulin, all normalized to the mean ratio in wild-type adipocytes without insulin. N = 6.
(F) Immunocytochemistry for TUJ1 and ISL-1 in wild-type and knockout HUES 9 motor neurons. Arrows indicate representative double-positive cells.
(G) Counts of wild-type and knockout HUES 9 (two clones each, D and E) motor neurons (TUJ1 and ISL-1 double-positive cells) treated with BDNF versus
proBDNF. N = 12. GDNF, glial cell-derived neurotrophic factor.
The error bars show SEM from experiments with biological replicates. p values were calculated with an unpaired t test. See also Figures S3, S4, and S5.
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proBDNF-induced programmed cell death in human motor
neurons.
AKT2 Regulates Insulin Signaling and Glucose
Metabolism in Hepatocytes and Adipocytes
The human AKT2 gene (encoding RAC-b serine/threonine-
protein kinase, also known as AKT2 or PKBb) has also been
implicated in the regulation of insulin sensitivity. Loss of function
of AKT2 in humans has been reported to result in severe insulin
resistance, as well as decreased body fat and partial lipodys-
trophy, attributed to reduced adipocyte differentiation (George
et al., 2004; Agarwal and Garg, 2006); also, Akt2 knockout
mice are resistant to the effects of insulin on glucosemetabolism
in liver and muscle, and they manifest lipoatrophy (Cho et al.,
2001; Garofalo et al., 2003). Recently, three patients with severe
hypoglycemia, hypoinsulinemia, and increased body fat were re-
ported to bear a missense mutation in AKT2, p.Glu17Lys (E17K)
(Hussain et al., 2011). Although the function of the mutant AKT2
E17K protein was assessed by heterologous overexpression
studies in cultured cell lines (HeLa and 3T3-L1) and interpreted
as being activated, the inability to study a physiologically rele-
vant phenotype (e.g., glucose metabolism) in physiologically
relevant tissues (e.g., human liver) precluded the conclusion
that the AKT2 mutation was causal for the metabolic disorder
in the patients.
We sought to unequivocally establish a dominant, activated
function of the AKT2 E17K mutant on glucose metabolism by
generating an allelic series of isogenic hPSC lines with wild-
type AKT2, knockout of AKT2, or a single AKT2E17K allele. We
designed TALENs to target the site of the E17K mutation in the
second coding exon (Figure 4A). In one round of targeting of
HUES 9 cells with the TALEN pair alone, we obtained 17 clones
with indels (out of 192 clones screened), none of whichwas com-
pound heterozygous for frameshift mutations. A second round of
TALEN targeting with a clone with one frameshift allele yielded
two clones compound heterozygous for frameshift mutations
(out of 96 clones screened). In parallel, we coelectroporated
wild-type HUES 9 cells with the TALEN pair and a 67 nt antisense
ssODN harboring the E17K missense variant, yielding three
AKT2E17K heterozygous clones (out of 192 clones screened)
(Figure S6A).Figure 4. AKT2 E17K Is a Dominant, Activating Mutation
(A) Generation of AKT2 knockout and E17K knockin hPSC clones with TALENs ta
Boxes in the wild-type sequence indicate the TALEN binding sites. The box in the
mutation in blue; the nucleotide in red indicates the missense mutation for E17K. D
insertion (asterisk) in clone A is 50-GACCTCCAGGTCCTG-30.
(B) Western blot for AKT2 and AKT1 in wild-type, knockout, and E17K HUES 9 H
(C) Immunocytochemistry for FoxO1 in HLCs (clones A and C) at baseline and a
(D) Ratios of glucose production to secreted albuminmass (ELISA) in wild-type, kn
D for E17K) treated with or without dexamethasone (Dex) and forskolin (Fsk) wi
without additives. Left panel, N = 4; right panel, N = 2.
(E) Ratios of triglyceride content to total protein content in wild-type, knockout, an
E17K), normalized to the mean ratio in wild-type adipocytes. N = 5.
(F) Ratios of glucose uptake to total protein content in wild-type, knockout, and E
E17K) treated with or without insulin, all normalized to the mean ratio in wild-typ
(G) IL-8 and adiponectin mass measured by ELISA in media collected from wild
knockout; C and D for E17K), normalized to mean levels from wild-type adipocy
The error bars show SEM from experiments with biological replicates. p values w
CeWe differentiated the allelic series of hPSC clones (two
clones each) into HLCs. No AKT2 protein was apparent in
the knockout cells, with comparable levels of AKT2 observed
in the wild-type and E17K cells (Figure 4B). We assessed the
regulation of the FoxO1 transcription factor, an AKT2 substrate
that upon phosphorylation is translocated from the nucleus to
the cytoplasm. In wild-type HLCs, FoxO1 was predominantly
nuclear at baseline and cytoplasmic after insulin stimulation;
in AKT2–/– HLCs, it was predominantly nuclear both at baseline
and after stimulation; and in AKT2E17K HLCs, it was predomi-
nantly cytoplasmic both at baseline and after stimulation (Fig-
ure 4C). We assessed glucose production in the allelic series
of HLCs and found that with all three genotypes, addition of
dexamethasone and forskolin to the media dramatically
increased glucose production; the further addition of insulin
decreased glucose production in the wild-type HLCs, but not
in the mutant HLCs (Figure 4D). In all media conditions,
glucose production was significantly higher in AKT2–/– HLCs
and lower in AKT2E17K HLCs compared to wild-type HLCs.
Similar trends were observed in the mRNA expression levels
of two genes involved in gluconeogenesis, G6PC and PCK1
(Figure S6B).
We also differentiated the AKT2 allelic series of hPSC clones
into white adipocytes and found that AKT2–/– adipocytes had
significantly decreased triglyceride content (32% reduction,
p = 0.0004) andAKT2E17K adipocytes had significantly increased
triglyceride content (26% increase, p = 0.005) (Figure 4E),
consistent with the fat-related phenotypes observed in patients
with AKT2 mutations. We observed a substantial increase in
glucose uptake in wild-type adipocytes upon treatment with
insulin (50% increase in two different experiments) but, as
with SORT1–/– adipocytes, we observed no significant change
in glucose uptake in AKT2–/– adipocytes with insulin (Figure 4F).
In contrast, AKT2E17K adipocytes displayed higher levels of
glucose uptake at baseline compared to wild-type adipocytes
(111% increase, p = 0.0001); upon treatment with insulin, there
was no further increase in glucose uptake, presumably because
the cells were in a constitutively active state with respect to
insulin signaling (Figure 4F). In the same vein, AKT2E17K adipo-
cytes displayed substantially increased secretion of inflam-
matory adipokines such as interleukin-18 (IL-8) (Figure 4G),
MCP1, and PAI-1 (Figure S6C). Finally, AKT2–/– and AKT2E17Krgeting exon 2. The underline indicates the codon encoding the E17K change.
ssODN sequence indicates the RsaI restriction site created by the synonymous
eletions and insertions in the two alleles of each clone are indicated. The 15 bp
LCs (A and B for knockout; C and D for E17K).
fter 15 min of insulin stimulation.
ockout, and E17KHUES 9HLCs (two clones each; A and B for knockout; C and
th or without insulin (Ins), all normalized to the mean ratios in wild-type HLCs
d E17K HUES 9 adipocytes (two clones each; A and B for knockout; C and D for
17K HUES 9 adipocytes (two clones each; A and B for knockout; C and D for
e adipocytes without insulin. N = 6.
-type, knockout, and E17K HUES 9 adipocytes (two clones each; A and B for
tes. N = 4.
ere calculated with an unpaired t test. See also Figures S3 and S6.
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Figure 5. PLIN1 Frameshift Mutations Produce Dominant-Acting and Truncated Proteins
(A) Generation of PLIN1 frameshift mutant hPSC clones with TALENs targeting exon 8. Boxes indicate the TALEN binding sites. Deletions in the one allele of each
clone are indicated.
(B) Immunocytochemistry for perilipin and BODIPY in wild-type, PLIN1558 (clone A), and PLIN1415 (clone B) adipocytes.
(C) Western blot for the N terminus of perilipin in wild-type, PLIN1558, and PLIN1415 adipocytes; the arrow indicates a truncated protein.
(D) Ratios of triglyceride content to total protein content in wild-type, PLIN1558, and PLIN1415 adipocytes. N = 3.
(E) Ratios of lipolysis activity (as measured by glycerol release) to total triglyceride content in wild-type, PLIN1558, and PLIN1415 adipocytes treated with or without
10 mM forskolin. N = 4.
The error bars show SEM from experiments with biological replicates. p values were calculated with an unpaired t test. See also Figure S7.
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ponectin, respectively (Figure 4G).
The opposing effects of the knockout and AKT2E17K alleles, in
addition to indicating that the effects were specific to AKT2 func-
tion and not the result of off-target effects, establish that E17K is
indeed a dominant, activating mutation in AKT2 and causal for
the hypoglycemia and increased body fat observed in the three
patients.
PLIN1 Frameshift Mutations Dominantly Alter Lipolysis
in Adipocytes
PLIN1 encodes the protein perilipin, the most abundant protein
coating lipid droplets in adipocytes, where it is required for
droplet formation and maturation, optimal triglyceride storage,
and the release of free fatty acids from the droplet (Brasaemle
et al., 2009). Frameshift mutations in PLIN1 have recently been
identified in patients with a novel autosomal-dominant subtype
of partial lipodystrophy (Gandotra et al., 2011). The frameshift
mutations found in patients result in a C-terminal elongation of
perilipin, with a significantly altered amino acid sequence. Mice
lacking Plin1 exhibit elevated levels of basal lipolysis in adipo-
cytes (Tansey et al., 2001; Zhai et al., 2010), which has been246 Cell Stem Cell 12, 238–251, February 7, 2013 ª2013 Elsevier Incsuggested as the mechanism by which patients harboring the
frameshift mutations develop lipodystrophy (Gandotra et al.,
2011). Mechanistic studies of these disease-causing mutations
have been limited to the overexpression of mutant and wild-
type human cDNAs in mouse 3T3-L1-derived adipocytes, with
the conclusion being that wild-type PLIN1, but not mutant
PLIN1, is able to inhibit basal lipolysis (Gandotra et al., 2011).
We designed TALENs to target the site of one of the natu-
rally occurring patient-specific mutations (Val398fs) in the eighth
coding exon of PLIN1 (Figure 5A). In a single round of targeting of
HUES 9 cells we identified 70 mutant clones (out of 293 clones
screened). We characterized two mutant clones, one of which
harbors a frameshift mutation that elongates perilipin to a length
of 558 amino acids (designated PLIN1558; wild-type perilipin has
522 amino acids)—very similar to the effect of the naturally
occurring Val398fs mutation—and the other of which has a
frameshift resulting in a C-terminal truncation of the protein
(415 amino acids; designated PLIN1415) (Figure S7A).
We differentiated the allelic series of hPSCs—wild-type,
PLIN1558, and PLIN1415—into white adipocytes and observed
a substantial reduction in the number of lipid-droplet-containing
cells, as well as smaller lipid droplets in PLIN1558 adipocytes.
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and Figure S7B). We confirmed the presence of perilipin pro-
tein in the adipocytes via western blot analysis (Figure 5C
and Figure S7C). We found that the PLIN1558 adipocytes had
significantly reduced triglyceride content (38% reduction com-
pared to wild-type adipocytes, p = 0.0009), whereas the
PLIN1415 adipocytes had similar triglyceride content to wild-
type adipocytes (Figure 5D). We also measured basal and for-
skolin-stimulated lipolysis and found that both PLIN1558 and
PLIN1415 adipocytes had increased basal lipolysis compared
to wild-type adipocytes (83% increase, p = 0.008, and 52%
increase, p = 0.04, respectively) (Figure 5E). Interestingly, both
the PLIN1558 and PLIN1415 mutations resulted in increased
lipolysis, though the effect was more marked with the PLIN1558
mutation; furthermore, there were significant differences in the
expression levels of adipocyte-specific genes between the
PLIN1558 and PLIN1415 cells, underscoring that the two different
frameshifts (one leading to elongation of perilipin, the other to
truncation) have distinct functional consequences (Figure S7D).
Together, these data point to the C-terminal elongated form of
perilipin, via a frameshift similar to naturally occurring mutations
in lipodystrophy patients, acting in a dominant fashion to alter
lipolysis and reduce triglyceride storage and lipid-droplet forma-
tion in human adipocytes.
TALENs Exhibit Minimal Off-Target Effects, but
Sequence Variants Abound
Because the extent of off-target effects of TALENs (i.e., muta-
genesis at other sites in the genome) in hPSCs remains to be
defined, we performed exome sequencing of six cell lines: the
parental HUES 1 cell line (clone X); the three SORT1 knockout
HUES 1 clones (clones A–C in Figure 3A); a control HUES 1
clone that had been grown in parallel with the SORT1 knockout
clones (i.e., had been exposed to the SORT1 exon 2 TALEN pair
but retained two wild-type alleles; cloneW); and a clone that had
been targeted in the CELSR2 gene with a different TALEN pair
(clone Y). It should be noted that TALENs virtually always induce
indels by NHEJ rather than single-nucleotide variants (SNVs).
Restricting our analysis to novel DNA sequence variants not
found in the parental HUES 1 cell line, we identified the known
on-target indels in SORT1 in clones A–C; otherwise, we identi-
fied just two indels in the exome, a 4 bp deletion in clone C in
the coding sequence of LARP6, resulting in a predicted frame-
shift mutation, and a 1 bp deletion in clone Y in an intron near
an exon-intron boundary of LUC7L3 (Table 2). Neither of these
sites is flanked by sequences resembling predicted TALEN
binding sites, arguing against (but not ruling out) the indels
being TALEN-mediated off-target effects. More noteworthy
were the 35 Sanger-sequencing-confirmed SNVs we discov-
ered across the five experimental and control clones (Table 2).
None of these SNVs lay near predicted off-target TALEN binding
sites (see next paragraph). It is more likely that these SNVs
represent intrinsic and perhaps unavoidable heterogeneity
among single-cell clones of the original pool of HUES 1 cells.
Arguing in favor of this interpretation, several of the SNVs were
shared by both experimental and control clones, implying
a common clonal origin within the original pool of HUES 1 cells.
The functional significance of these SNVs is unclear, but
the majority resulted in missense mutations, and at least oneCelay in a well-established disease gene (DMD, responsible for
Duchenne muscular dystrophy).
We also performed whole-genome sequencing of the same
six cell lines. Because the sequencing was performed at low
coverage (6–123 coverage on average), it was not possible to
perform de novo genome assembly and ascertain all sequence
variation among the genomes. Instead, we used the sequencing
data to interrogate the sites in the genome at which one or the
other TALEN of the SORT1 exon 2 TALEN pair would be most
likely to bind based on a weighted TAL monomer-nucleotide
association probability matrix developed by Doyle et al. (2012),
and would thus be most likely to induce an off-target sequence
change. About 100,000 potential off-target genomic sites were
identified; we screened all of these sites for evidence of nearby
indels. Besides the known SORT1 indels in clones A–C, we iden-
tified no indels meeting our criteria.
Thus, although we are not able to completely rule out TALEN
off-target effects, we conclude that off-target indels rarely occur
based on the results of the exome and whole-genome sequence
analyses. However, extrapolating to the entire genome, we
expect that each clonal cell line harbors hundreds of SNVs that
distinguish it from other cell lines derived from the same pool
of parental cells. Thus, it may be virtually impossible to derive
truly isogenic cell lines, even with the minimized manipulation
of cells entailed by our genome-editing system.
DISCUSSION
In our studies we have used human model systems to generate
strong evidence that apoB-100 is critical for HCV replication in
human hepatocytes; that sortilin reduces apoB secretion by
human hepatocytes, facilitates insulin-mediated glucose uptake
by human adipocytes, and is necessary for proBDNF-mediated
motor-neuron apoptosis; that AKT2 E17K is a gain-of-function
mutation that leads to reduced glucose production in human
hepatocytes and increased triglyceride content in human adipo-
cytes; and that PLIN1 frameshift mutations increase basal
lipolysis in human adipocytes. More generally, these findings
highlight the various types of studies to which genome editing
in human cells may be applied for obtaining novel biological
insights.
We note that genome-editing technology is rapidly advancing,
and we anticipate that improvements in the engineering of
TALENs will continue to make genome editing more rapid
and efficient. Indeed, since we established our system, high-
throughput automated assembly methods have been reported
(Reyon et al., 2012; Briggs et al., 2012), as well as the character-
ization of TAL monomers with improved nucleotide-binding
specificity (Streubel et al., 2012; Cong et al., 2012). Although
our specific TALEN assembly platform does not incorporate
these latest advancements, in principle any up-to-date assembly
platform that is paired to a delivery methodology similar to ours
should be able to achieve efficient genome editing on a timescale
of less than a month.
Whatever the assembly platform, our studies suggest that
TALENs incur a low burden of off-target effects but that there
is nevertheless significant clone-to-clone genetic variation in
the form of SNVs; even if not secondary to TALEN use, they
cannot be ignored. The ease and rapidity of TALEN-mediatedll Stem Cell 12, 238–251, February 7, 2013 ª2013 Elsevier Inc. 247
Table 2. Clonal Sequence Variants Detected by Exome Sequencing and Their Predicted Effects on Protein Products
Chr Pos Ref Alta Gene Clone Ab Clone B Clone C Clone W Clone Y
1 21014224 G T KIF17 – – S432Y – –
1 90178297 G A LRRC8C – – – P56P –
1 149921554 C T OTUD7B – – – – Q367Q
2 109347284 T C RANBP2 – – – F39F –
2 113820048 C A IL36RN – – – – L88I
2 173330424 C T ITGA6 – intronic – – –
3 132319348 T C CCRL1 – – – – V36A
3 193002674 G T ATP13A5 intronic – intronic intronic –
4 113568377 GAAGA G LARP7 – – frameshiftc – –
6 152652970 C A SYNE1 – – – – A4284S
7 2260574 C T MAD1L1 – – – – G47D
7 22179660 G C RAPGEF5 L601V – – – –
8 15508246 C T TUSC3 – – R117C – –
9 33354142 G A NFX1 E130K – – – –
10 75541848 C T CHCHD1 – S5S – – –
11 124095534 G A OR8G2 – – G46E – –
12 80752469 G T OTOGL – C2026F – – –
12 101750754 G T UTP20 R1862I – R1862I R1862I –
12 105445861 G T ALDH1L2 – intronic – – –
14 21967435 C A METTL3 – intronic – – –
15 43827249 G T PPIP5K1 – – P1071T – –
15 48805891 C A FBN1 – – intronic – –
15 90631649 C A IDH2 – – – – W155L
16 20043135 C A GPR139 – S328S – – –
17 11998899 G A MAP24K4 R145Q – R145Q R145Q –
17 48817653 AT A LUC7L3 – – – – intronicd
17 73567174 G T LLGL2 – L712L – – –
17 79226178 C A SLC38A10 – – – A588S –
18 30992086 G T C18orf34 – – – – intronic
19 9028296 G T MUC16 – – – – L12166M
19 56552245 G T NLRP5 intronic – intronic intronic –
20 60498685 G T CDH44 – E425D – – –
22 37325592 C A CSF2RB D100E – D100E D100E –
22 39078278 A T TOMM22 – intronic – – –
X 32328257 G T DMD – A1897D – – –
X 48558634 C T SUV39H1 – – T106T – –
X 135956509 C A RBMX – – – – S323I
Chr, chromosome; Pos, position; Ref, reference allele; Alt, alternate allele.
aAlternate allele compared to reference allele in parental HUES 1 cell line (clone X), confirmed by Sanger sequencing.
bClones A, B, and C are SORT1–/– clones in HUES 1; clone W is a wild-type (SORT1+/+) clone in HUES 1 that was exposed to SORT1 transcription
activator-like effector nucleases (TALENs), from the same pool as clones A–C; clone Y is a wild-type (SORT1+/+) clone that was exposed to a different
set of TALENs (targeting CELSR2).
cThe surrounding sequence is CAGAA GAGAA GAAAA AGAAA AAGAA GAAGA AAGGC CGAAT GAAAA AGGAA GACAA.
dThe surrounding sequence is ATAAT CACAG ATAAT TTATA CAATT ATATT TTTTC CCCCA GGTCC GTGTG AAAAA.
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viate any concerns about off-target effects or other potential
confounding by clonal sequence variation. As we have demon-
strated with SORT1, it is straightforward to (1) generate multiple
distinct mutant cell lines with each TALEN pair, (2) use distinct
TALEN pairs to target different sites in a gene, (3) generate
mutant clones in different cell lines with different genetic back-248 Cell Stem Cell 12, 238–251, February 7, 2013 ª2013 Elsevier Incgrounds, and (4) perform reconstitution experiments in knockout
clones. Having used all of these approaches, we are able to
conclude with great confidence that the observed cellular
phenotypes are indeed related to SORT1 function. We suggest
that using at least one of these approaches should become de
rigeur for future genetic studies in order to minimize confounding
by clonal sequence variation..
Cell Stem Cell
Isogenic Cellular Models of DiseaseGiven the ability to use TALENs to readily insert specific gene
variants into cells, the current enthusiasm for the generation and
comparison of ‘‘disease’’ iPSC lines from patients with genetic
disorders and ‘‘control’’ iPSC lines from unmatched healthy indi-
viduals should shift to the use of genome editing to engineer
isogenic cell lines with and without disease mutations. The
time required to recruit a patient for the donation of tissue from
which to make iPSCs (assuming such a patient is readily acces-
sible, which may not be the case for rare disorders), to perform
reprogramming for deriving iPSC clones, to perform quality
control for identifying clones that are pluripotent and that will
readily differentiate into the desired cell type, and then to under-
take differentiation and phenotypic studies—in the absence of
isogenic control cell lines—is a minimum of six months and
usually longer. Within a shorter time frame, we have found it to
be quite feasible to use TALENs to edit a well-characterized
and prevalidated (with respect to differentiation capacity)
hPSC line and yield both mutant cell lines and isogenic control
cell lines, allowing for a more rigorous study design, and to
undertake differentiation and phenotypic studies, without any
need for patient contact.
Thepotential advantagesofferedbyprevalidatedwild-typecell
lines notwithstanding, there are many disorders for which the
genetic background (i.e., modifier genes) plays a significant role
indeterminingwhether diseasemutations result in clinical pheno-
types. In these cases, it will be important to use iPSC lines from
patients with clinically apparent diseases in order to have cell
lines with the correct genetic backgrounds for complete disease
penetrance (whereas wild-type cell lines may have nonpermis-
sive genetic backgrounds). Genome editing with TALENs
could be readily applied to patient-specific iPSC lines to ‘‘cure’’
disease mutations and generate appropriate isogenic control
lines. Indeed, the most robust study design possible may be to
assess both the effect of inserting a disease mutation into a
wild-type cell line, thereby testing the sufficiency of the mutation
for disease, and the effect of removing a disease mutation from
a patient-specific iPSC line, thereby testing the necessity of the
mutation for disease. Certainly the rapidity and efficiency of
genome editing with TALENs should make it feasible to test the
effects of a diseasemutation in a variety of genetic backgrounds.
Finally, genome editing potentially allows for the interrogation
of a large number of DNA sequence variants, such as those now
emerging from next-generation sequencing studies of human
populations, on a single genetic background. Creating a robust
allelic series of isogenic cell lines represents an approach that
hitherto has only been possible in nonmammalian organisms.
Such studies will represent a significant advance in our ability
to dissect genotype-phenotype relationships and thereby better
elucidate human biology and disease.EXPERIMENTAL PROCEDURES
TALEN Construction
TALEN genomic binding sites were chosen to be 15 bp in length or, in a few
cases, 13 bp in length such that the target sequence between the two binding
sites was between 14 and 18 bp in length; each binding site was anchored by
a preceding T base in position ‘‘0’’ as has been shown to be optimal for natu-
rally occurring TAL proteins (Moscou and Bogdanove, 2009; Boch et al., 2009).
A library of 832 tetramer or trimer TAL repeats was constructed using methods
based on the PCR-based protocol of Zhang et al. (2011); thesemultimers wereCedesigned to have complementary sticky ends when digested out of library
plasmids with the type IIs restriction enzyme BsmBI. As outlined in Figure 1,
multimers were assembled into an array and subcloned into a full-length
TALEN harboring, in order, an N-terminal FLAG tag, a nuclear localization
signal, the N-terminal portion of the TALE PthXo1 from the rice pathogen
X. oryzae pv. oryzae (a kind gift of Dr. Daniel Voytas, University of Minnesota)
lacking the first 176 amino acids (after Miller et al., 2011), the engineered TAL
repeat array, the following 63 amino acids from the corresponding C-terminal
portion of PthXo1 (after Miller et al., 2011), and one of two enhanced FokI
domains. The FokI domains used were obligate heterodimers with both the
Sharkey (Guo et al., 2010) and ELD:KKR (Doyon et al., 2011) mutations for
enhancing cleavage activity, engineered by PCR. Each TALEN was in a
plasmid with the CAG promoter for optimal expression in hPSCs, with the
TALEN being coexpressed with a fluorescent marker (enhanced green fluores-
cent protein, mCherry [Clontech], or turbo red fluorescent protein [Evrogen])
via an intervening viral 2A sequence. The generic TALEN protein sequences
are shown in Figure S1A. All reagents, protocols, and plasmid sequences
needed for generating TALENs and performing genome editing by themethods
described in this manuscript will be available to academic researchers through
Addgene (http://www.addgene.org/TALEN_genome_editing_collection).
Cell Culture, Transfection or Electroporation, and Sorting
HuH-7 (CD81hi) cells were grown in adherent culture in Dulbecco’s modified
Eagle’s medium High Glucose containing glutamine and pyruvate (Invitrogen)
and supplemented with 10% fetal bovine serum, penicillin, and streptomycin.
Transfection of the plasmids expressing the APOB TALEN pair into HuH-7
cells was performed using FuGENE 6 (Roche) in 10 cm tissue-culture plates
according to manufacturer instructions. HUES 1 and HUES 9 cells (Cowan
et al., 2004) were grown in feeder-free adherent culture in chemically defined
mTeSR1 (STEMCELL Technologies) supplemented with penicillin and strepto-
mycin on plates precoated with Geltrex matrix (Invitrogen). The cells were dis-
associated into single cells with Accutase (Invitrogen), and 10million cells were
electroporated with 50 mg of the TALEN pair (25 mg of each plasmid), or with
a mix of 30 mg of the TALEN pair (15 mg of each plasmid) and 30 mg of the
ssODN (50-CAGGA AGTAC CGTGG CCTCC AGGTC TTGAT GTACT TACCT
GAAAT GAGGC AGGAA GGGAG GGAGA GA-30) in a single cuvette and re-
plated as previously described (Schinzel et al., 2011). The cells were collected
from the culture plates 48 hr posttransfection or postelectroporation by trypsin
or Accutase treatment, respectively, and resuspended in PBS. Cells express-
ing green and/or red fluorescentmarkers were collected by FACS (FACSAria II;
BD Biosciences) and replated on 10 cm tissue-culture plates at 15,000 cells/
plate to allow for recovery in growth media.
Isolation of Targeted Clonal Cell Populations
Post-FACS, the cells were allowed to recover for 7–10 days, after which single
colonies were manually picked, dispersed, and replated individually to wells of
96-well plates. Colonies were allowed to grow to near confluence over the next
7 days, at which point they were split using trypsin (for HuH-7 cells) or Accu-
tase (for hESCs) and replica-plated for the creation of a working stock and
a frozen stock. The working stock was grown to confluence. Genomic DNA
was extracted in 96-well format from working stocks in lysis buffer (10 mM
Tris [pH 7.5], 10mMEDTA, 10mMNaCl, 0.5%Sarcosyl) containing proteinase
K at 56C overnight in a humidified chamber. Genomic DNA was precipitated
by the addition of 95%ethanol containing 75mMNaCl for 1 hr at room temper-
ature. The DNA was then washed two times in 70% ethanol, allowed to dry at
room temperature, and then resuspended in nuclease-free water.
Genotyping at the TALEN target site was then performed for each sample by
PCR amplication (94C, 30 s; 56C, 30 s; 68C, 30 s) using FastStart Taq
(Roche) and a primer pair designed to yield small amplicons (150–200 bp)
around the target site. Amplicons were subjected to electrophoresis on
2.5% agarose gels to discriminate clones with indels, with positive clones
having a band or bands visibly shifted in size from the baseline (see Figures
S1B and S6A for examples); for AKT2 E17K candidate clones, the amplicons
were digested with RsaI for 1 hr and subjected to electrophoresis, with positive
clones displaying cleavage products (Figure S6A). For a subset of the poten-
tially positive clones, PCR amplicons were subcloned using the TOPO TA
Cloning Kit (Invitrogen) and subjected to numerous sequence reads for confir-
mation of the presence of mutant alleles; in a similar fashion, a subset of thell Stem Cell 12, 238–251, February 7, 2013 ª2013 Elsevier Inc. 249
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confirmed compound heterozygous mutant alleles (or the AKT2 E17K muta-
tion) or confirmed to be wild-type were retrieved from the frozen stocks and
expanded for further experiments. When no compound heterozygous clones
were identified, a heterozygous clone with one mutant allele was expanded
and subjected to a second round of TALEN targeting.
Differentiation of hPSCs into HLCs, White Adipoctyes, and Motor
Neurons
Differentiation was performed following the protocols of Si-Tayeb et al. (2010),
Ahfeldt et al. (2012), and Di Giorgio et al. (2008) and Chambers et al. (2009).
Details are given in Supplemental Experimental Procedures.
ELISAs, Immunocytochemistry, and Western Blot Analysis
These procedures were performed using standard methods. Details are given
in Supplemental Experimental Procedures.
Glucose Production, Glucose Uptake, Triglyceride Content, and
Lipolysis Assays
Glucose production and glucose uptake were measured using protocols
adapted from Hagiwara et al. (2012) and Ahfeldt et al. (2012), respectively.
Details of the various procedures are given in Supplemental Experimental
Procedures.
Quantitative RT-PCR
Quantitative RT-PCR (qRT-PCR) was performed using standard methods.
Details and oligonucleotide sequences are given in Supplemental Experi-
mental Procedures.
HCV Infection of HuH-7 Cells
Details are given in Supplemental Experimental Procedures.
Exome and Whole-Genome Sequence Analyses
Exome sequencing and whole-genome sequencing were performed as previ-
ously described (Gnirke et al., 2009; Stransky et al., 2011). Procedural and
analytical details are given in Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.stem.2012.11.011.
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